ATE557010T1 - Triazolonderivat - Google Patents

Triazolonderivat

Info

Publication number
ATE557010T1
ATE557010T1 AT10157326T AT10157326T ATE557010T1 AT E557010 T1 ATE557010 T1 AT E557010T1 AT 10157326 T AT10157326 T AT 10157326T AT 10157326 T AT10157326 T AT 10157326T AT E557010 T1 ATE557010 T1 AT E557010T1
Authority
AT
Austria
Prior art keywords
optionally substituted
independently represent
represent hydrogen
represents optionally
triazolone derivative
Prior art date
Application number
AT10157326T
Other languages
English (en)
Inventor
Richard Clark
Fumiyoshi Matsuura
Kazunobu Kira
Shinsuke Hirota
Hiroshi Azuma
Tadashi Nagakura
Tatsuo Horizoe
Kimiyo Tabata
Kazutomi Kusano
Takao Omae
Atsushi Inoue
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE557010T1 publication Critical patent/ATE557010T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT10157326T 2006-03-24 2007-03-22 Triazolonderivat ATE557010T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2006083486 2006-03-24
US78668706P 2006-03-29 2006-03-29
JP2006162594 2006-06-12
US80487806P 2006-06-15 2006-06-15
JP2006218819 2006-08-10
US83841806P 2006-08-18 2006-08-18

Publications (1)

Publication Number Publication Date
ATE557010T1 true ATE557010T1 (de) 2012-05-15

Family

ID=38950011

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10157326T ATE557010T1 (de) 2006-03-24 2007-03-22 Triazolonderivat
AT07739256T ATE491694T1 (de) 2006-03-24 2007-03-22 Triazolonderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07739256T ATE491694T1 (de) 2006-03-24 2007-03-22 Triazolonderivat

Country Status (25)

Country Link
US (3) US7816522B2 (de)
EP (2) EP2000465B1 (de)
JP (1) JP5016592B2 (de)
KR (1) KR101362024B1 (de)
AT (2) ATE557010T1 (de)
AU (1) AU2007230346B2 (de)
BR (1) BRPI0709101A2 (de)
CA (1) CA2647423C (de)
CY (1) CY1111271T1 (de)
DE (1) DE602007011231D1 (de)
DK (1) DK2000465T3 (de)
HR (1) HRP20110054T1 (de)
IL (1) IL194188A (de)
MX (1) MX2008012031A (de)
MY (1) MY146537A (de)
NO (1) NO20084441L (de)
NZ (1) NZ571441A (de)
PL (1) PL2000465T3 (de)
PT (1) PT2000465E (de)
RS (1) RS52030B (de)
SA (1) SA07280131B1 (de)
SI (1) SI2000465T1 (de)
TW (1) TWI389894B (de)
WO (1) WO2007111212A1 (de)
ZA (1) ZA200805758B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041119A1 (ja) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
WO2007111212A1 (ja) 2006-03-24 2007-10-04 Eisai R & D Management Co., Ltd. トリアゾロン誘導体
JPWO2009038157A1 (ja) * 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 2,3−ジヒドロ−イミノイソインドール誘導体
EA201000656A1 (ru) * 2007-10-26 2010-12-30 Астразенека Аб Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
TW201206905A (en) * 2010-05-20 2012-02-16 Eisai R & Amp D Man Co Ltd Prodrug of triazolone compound
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CN102993109A (zh) * 2012-12-03 2013-03-27 浙江工业大学 一种脒化合物的制备方法
JP6404230B2 (ja) 2012-12-20 2018-10-10 インセプション 2、 インコーポレイテッド トリアゾロン化合物およびその使用
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
EP3588064B1 (de) * 2017-02-23 2022-09-07 IHI Corporation Oh radikaldetektionssonde, oh-radikalmessvorrichtung und oh-radikalmessverfahren

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005000A (en) * 1931-07-18 1935-06-18 L N Miller Engineering Corp Differential motor
EP0019586A1 (de) 1979-05-11 1980-11-26 Ciba-Geigy Ag Neue antithrombotische Kombinationspräparate
SU1512055A1 (ru) 1987-12-04 1992-07-23 Пермский фармацевтический институт Дигидрохлорид гидразида N-ацетил-N-аллилантраниловой кислоты, про вл ющий антиагрегатную активность по отношению к тромбоцитам плазмы крови
CN1268116A (zh) 1997-08-27 2000-09-27 橘生药品工业株式会社 3-脒基苯胺衍生物,活化血凝固因子x抑制剂和制备这些物质的中间体
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
CA2321538A1 (en) 1998-03-27 1999-10-07 Dupont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
HK1043106A1 (zh) 1998-12-14 2002-09-06 F. Hoffmann-La Roche Ag 苯基甘氨酸衍生物
EP1144373B1 (de) * 1999-01-13 2005-10-19 Genentech, Inc. Serinprotease-inhibitoren
FR2791683A1 (fr) 1999-03-30 2000-10-06 Synthelabo Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
FR2793247B1 (fr) 1999-05-04 2001-06-22 Synthelabo Derives de 6-[[(aryl et heteroaryl)oxy]methyl]naphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
EP1162194A1 (de) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Auf Faktor VIIa inhibitorisch wirkende (Thio)-Harnstoff Verbindungen, Verfahren zu deren Herstellung und deren Verwendung
US7476688B2 (en) 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
EP1312602A1 (de) 2001-11-15 2003-05-21 Eisai Co., Ltd. Amidinoderivate und diese enthaltende antikoagulierende und antithrombotische Wirkstoffe
JP4209659B2 (ja) 2001-11-15 2009-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 アミジノ誘導体並びにそれを用いた抗血液凝固剤および血栓症治療剤
AU2003284001A1 (en) * 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
EP1479679A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazolderivate als Faktor-Xa-Inhibitoren
WO2006041119A1 (ja) 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
US7576098B2 (en) 2004-12-08 2009-08-18 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor VIIa
WO2007111212A1 (ja) 2006-03-24 2007-10-04 Eisai R & D Management Co., Ltd. トリアゾロン誘導体
JPWO2009038157A1 (ja) 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 2,3−ジヒドロ−イミノイソインドール誘導体

Also Published As

Publication number Publication date
NO20084441L (no) 2008-12-22
HK1123808A1 (en) 2009-06-26
EP2000465A1 (de) 2008-12-10
AU2007230346A1 (en) 2007-10-04
NZ571441A (en) 2010-08-27
US20100190783A1 (en) 2010-07-29
EP2000465B1 (de) 2010-12-15
SA07280131B1 (ar) 2010-03-08
RS52030B (sr) 2012-04-30
TW200745063A (en) 2007-12-16
US8163787B2 (en) 2012-04-24
KR20090014341A (ko) 2009-02-10
DE602007011231D1 (de) 2011-01-27
CY1111271T1 (el) 2015-08-05
JPWO2007111212A1 (ja) 2009-08-13
US20080015199A1 (en) 2008-01-17
TWI389894B (zh) 2013-03-21
EP2194046B1 (de) 2012-05-09
AU2007230346B2 (en) 2011-12-22
ZA200805758B (en) 2009-12-30
HRP20110054T1 (hr) 2011-02-28
IL194188A (en) 2013-08-29
CA2647423C (en) 2015-02-17
KR101362024B1 (ko) 2014-02-11
US7928228B2 (en) 2011-04-19
MY146537A (en) 2012-08-15
MX2008012031A (es) 2008-10-02
SI2000465T1 (sl) 2011-04-29
WO2007111212A1 (ja) 2007-10-04
US7816522B2 (en) 2010-10-19
US20110112109A1 (en) 2011-05-12
EP2000465A4 (de) 2009-08-26
DK2000465T3 (da) 2011-02-07
JP5016592B2 (ja) 2012-09-05
BRPI0709101A2 (pt) 2011-06-28
PL2000465T3 (pl) 2011-05-31
CA2647423A1 (en) 2007-10-04
EP2194046A1 (de) 2010-06-09
ATE491694T1 (de) 2011-01-15
PT2000465E (pt) 2011-02-10

Similar Documents

Publication Publication Date Title
CY1111271T1 (el) Παραγωγο τριαζολονης
DK1277736T3 (da) Hidtil ukendte bicykliske forbindelser
ATE556058T1 (de) 1-(2h)-isochinolonderivat
EP1798226A4 (de) Triazolderivat
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
ATE544744T1 (de) Verfahren zur herstellung von benzoesaure derivaten
WO2007006409A3 (de) Herbizid-safener-kombination
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
WO2009038157A1 (ja) 2,3-ジヒドロ-イミノイソインドール誘導体
ATE297902T1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
DK1186607T3 (da) Optisk aktive pyrrolopyridazinforbindelser
ATE525386T1 (de) 3'-ethynylcytidinderivat
IL187917A (en) Compounds 1– (Converted phenyl) -pyreno [3,4– b] [1] benzofuran-3-van
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων
MA31206B1 (fr) Dérivés cyclohexyl amide d'acide carboxylique aryle
ATE361925T1 (de) Pyrrolopyridazin-verbindungen
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
NO20053997D0 (no) Oligosaccharidderivat
ATE284884T1 (de) Triazolderivate mit amidbindungen
ATE279417T1 (de) Neue carbapenem-derivate
ATE522499T1 (de) Verfahren zur herstellung von tamsulosin und seinen derivaten
TH96118A (th) กรรมวิธีทางเคมี